Metabolic syndrome in Alzheimer's disease: Clinical and developmental influences;Síndrome metabólico en la enfermedad de Alzheimer: Influencias clínicas y evolutivas

Revista de Neurologia

Volumn 46, Issue 1, 2008, Pages 13-17

  Vilalta Franch, Joan ^a   Lopez Pousa S ^a   Garre Olmo, J ^a   Turon Estrada A ^a   Pericot Nierga, I ^a  

^a HOSPITAL SANTA CATERINA   (Spain)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Cognitive impairment; Functional impairment; Memantine; Metabolic syndrome; Mortality

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; OLANZAPINE; RISPERIDONE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONDUCT DISORDER; DAILY LIFE ACTIVITY; DEMENTIA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART DISEASE; HUMAN; INCIDENCE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; MINI MENTAL STATE EXAMINATION; MORTALITY; OUTPATIENT; OUTPATIENT DEPARTMENT; RATING SCALE; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 38549159932     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4601.2007362     Document Type: Article

References (50)

1. De la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 2002; 977: 196-215.
2. Sacks FM. Metabolic syndrome: epidemiology and consequences. J Clin Psychiatry 2004; 65: 3-12.
3. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: 1059-62.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
5. Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. Med J Aust 2006; 185: 445-9.
6. Demacker PNM. The metabolic syndrome: definition, pathogenesis and therapy. Eur J Clin Invest 2007; 37: 85-9.
7. Opie LH. Metabolic syndrome. Circulation 2007; 115: e32-5.
8. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-78.
9. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbatecola AM, et al. Insulin resistance in cognitive impairment. The InCHIANTI study. Arch Neurol 2005; 62: 1067-72.
10. Razay G, Vreugdenhil A, Wilcok G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64: 93-6.
11. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hänninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease. A population-based study. Neurology 2006; 67: 843-7.
12. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord 2007; 24: 185-92.
13. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmr RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of aging study. J Am Geriatr Soc 2007; 55: 758-62.
14. Van den Berg E, Biessels GJ, De Craen AJ, Westendorp RG. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007; 69: 979-85.
15. Gause-Nilsson I, Gherman S, Kumar-Dey D, Kennerfalk A, Steen B. Prevalence of metabolic syndrome in an elderly Swedish population. Acta Diabetol 2006; 43: 120-6.
16. Ford ES, Gile WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA 2002; 287: 356-9.
17. Sandhofer A, Iglseder B, Paulweber B, Ebenbichler CF, Patsch JR. Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest 2007; 37: 109-16.
18. López-Pousa S, Vilalta-Franch J, Llinàs-Reglà J, Garre-Olmo J, Román GC. Incidence of dementia in a rural community in Spain. The Girona cohort study. Neuroepidemiology 2004; 23: 170-7.
19. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-9.
20. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
21. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-14.
22. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006; 119: 812-9.
23. McNeill AM, Katz R, Girman CJ, Rosamond WD, Wagenknecht LE, Barzilay JI, et al. Metabolic syndrome and cardiovascular disease in older people: the Cardiovascular Health Study. J Am Geriatr Soc 2006; 54: 1317-24.
24. Ravaglia G, Forti P, Maioli F, Bastagli L, Chiappelli M, Montesi F, et al. Metabolic syndrome. Prevalence and prediction of mortality in elderly individuals. Diabetes Care 2006; 29: 2471-6.
25. Folstein MF, Folstein SE, McHugh PR. Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
26. Blessed G, Tomilson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
28. Reisberg B, Ferris SH, De Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9.
29. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16: 622-6.
30. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, for the Conference Participants. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
31. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
32. Sundstrom J, Vallhagen E, Riserus U, Byberg L, Zethelius B, Berne C, et al. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006; 29: 1673-4.
33. Monami M, Lambertucci L, Ungar A, Pieri M, Masotti G, Marchionni N, et al. Is the third component of metabolic syndrome really predictive of outcomes in type 2 diabetic patients? Diabetes Care 2006; 29: 2515-7.
34. Després JP, Lemieu I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-7.
35. Hubert HB, Feinleib M, McNamara PM, Castelli WP, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-77.
36. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-85.
37. Lee IM, Manson JE, Hennekens CH, Paffenbarger RS Jr. Body weight and mortality. A 27-year follow-up of middle-aged men. JAMA 1993; 270: 2823-8.
38. Van Itallie TB. Obesity: adverse effects on health and longevity. Am J Clin Nutr 1979; 32: 2723-33.
39. Kanaya AM, Vittinghoff E, Shlipak MG, Resnick HE, Visser M, Grady D, et al. Association of total and central obesity with mortality in postmenopausal women with coronary heart disease. Am J Epidemiol 2003; 158: 1161-70.
40. Frisoni GB, Galluzzi S, Bresciani L, Zanetti O, Geroldi C. Mild cognitive impairment with subcortical vascular features: clinical characteristics and outcome. J Neurol 2002; 249: 1423-32.
41. Vermeer SE, Hollander M, Van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM, Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126-9.
42. Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A, Soininen H. Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. CNS Drugs 2002; 16: 435-44.
43. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabetic Medicine 1999; 16: 93-112.
44. Allen KV, Frier BM, Strachan MW. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004; 490: 169-75.
45. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001; 56: 1683-9.
46. Notkola IL, Sulkava R, Perkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14-20.
47. Lee JH, Olichney JM, Hansen LA, Hofstetter CR, Thal LJ. Small concomitant vascular lesions do not influence rates of cognitive decline in patients with Alzheimer disease. Arch Neurol 2000; 57: 1474-9.
48. Jellinger KA. Small concomitant cerebrovascular lesions are not important for cognitive decline in severe Alzheimer disease. Arch Neurol 2001; 58: 520-1.
49. Kovari E, Gold G, Herrmann FR, Canuto A, Hof PR, Michel JP, et al. Cortical microinfarcts and demyelination significantly affect cognition in brain ageing. Stroke 2004; 35: 410-4.
50. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.